Company intelligence / Profile preview

Laboratory Skin Care

Hayward, California, United Stateslscskincare.com ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

LSC’s Hydroxysomes® technology has demonstrated commercial success with global brands. Their products are clinically tested to kill 99.9% of microorganisms while being gentle enough for daily use on sensitive skin. The company holds over 100 issued and pending patents wholly owned by LSC.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device (dermal delivery platform)Small molecule (bioactives in skincare)
Industry: Consumable Medical Devices

Drug pipeline

2 assets

Antimicrobial Cleanser

Commercial

Indications: Skin protection, Skin hygiene

1 more asset in the full pipeline.

Request access →

Partnerships

Not publicly disclosed; products have been licensed to several leading global skincare brands

Beyond the preview

Go deeper on Laboratory Skin Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratory Skin Care.

Explore the full profile